Kevin Litchfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Kevin Litchfield has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Samra Turajlic
Cancer Dynamics Laboratory, Francis Crick Institute, London, UK; Cancer Dynamics Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK; Cancer Research UK Manchester Institute, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
124 shared publications - James Larkin
Royal Marsden NHS Foundation Trust, London, UK
108 shared publications - Ajitha Rajan
School of Informatics, University of Edinburgh, Edinburgh, United Kingdom
71 shared publications - Aleksander Palkowski
Faculty of Electrical and Control Engineering, Gdansk University of Technology, 80-233 Gdansk, Poland
71 shared publications - Alexander Laird
Department of Urology University of Edinburgh, Western General Hospital Edinburgh UK
71 shared publications - Catia Pesquita
LASIGE, Faculdade de Ciências da Universidade de Lisboa
71 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Nature
- p. 1-12
A preinvasive regulatory T cell axis for lung cancer interception
Late-stage non-small cell lung cancer (NSCLC) is rarely curable 1 , underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis 2,3 . Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4 + T cells (eT reg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eT reg cells. Circulating eT reg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eT reg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eT reg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF + T reg cells and T reg cell-rich peribronchial immature tertiary lymphoid structures (iTLSs). Immune interception via phosphoinositide 3-kinase-δ (PI3Kδ) inhibition abrogated formation of T reg cell-rich iTLSs, reduced circulating and pulmonary T reg cells, increased local conventional type 1 dendritic cells (cDC1s) and reduced lung tumour incidence and size. These data reveal a conserved eT reg cell network that emerges across tissues during early pulmonary tumorigenesis and provide a theranostic framework to track and target preinvasive immune regulation for lung cancer interception.
- 7 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Open AccessA preinvasive regulatory T cell axis for lung cancer interception
Late-stage non-small cell lung cancer (NSCLC) is rarely curable 1 , underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis 2,3 . Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4 + T cells (eT reg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eT reg cells. Circulating eT reg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eT reg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eT reg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF + T reg cells and T reg cell-rich peribronchial immature tertiary lymphoid structures (iTLSs). Immune interception via phosphoinositide 3-kinase-δ (PI3Kδ) inhibition abrogated formation of T reg cell-rich iTLSs, reduced circulating and pulmonary T reg cells, increased local conventional type 1 dendritic cells (cDC1s) and reduced lung tumour incidence and size. These data reveal a conserved eT reg cell network that emerges across tissues during early pulmonary tumorigenesis and provide a theranostic framework to track and target preinvasive immune regulation for lung cancer interception.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S18 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S18: Regression - Mitochondria Count (Log10). Linear regression was applied. All results are adjusted by sex, age of sampling and stage. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S18 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S18: Regression - Mitochondria Count (Log10). Linear regression was applied. All results are adjusted by sex, age of sampling and stage. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Note 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Inputting information from previous TRACERx Renal studies
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Note 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Inputting information from previous TRACERx Renal studies
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S8: Summary of recurrent structural variant events. ChRCC, chromophobe renal cell carcinoma; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S8: Summary of recurrent structural variant events. ChRCC, chromophobe renal cell carcinoma; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S16: Clinical Correlations with age, sex, stage and grade. Patient sex uses female sex as baseline. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S16: Clinical Correlations with age, sex, stage and grade. Patient sex uses female sex as baseline. Results with P < 0.05 are highlighted. ChRCC, chromophobe renal cell carcinoma; CN, copy number state; LoH, loss of heterozygosity; MB, megabase; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant; SV, structural variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
The identification of cancer drivers is a cornerstone to the delivery of precision oncology. So far, sequencing of renal cell cancer (RCC) has largely been confined to the clear cell subtype of RCC. In contrast, sequencing analyses of the less common forms of RCC, papillary RCC (pRCC) and chromophobe RCC (ChRCC), have so far been limited. We analyzed whole-genome sequencing data on 164 tumor–normal pairs from the Genomics England 100,000 Genomes Project, providing a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genomic features, including mutational signatures, intratumor heterogeneity, and analysis of extrachromosomal DNA formation. Our research establishes correlations between genomic alterations and histologic diversification and the extent to which genetically-mediated immune escape contributes to the development of these RCC subtypes.Implications:We demonstrate the distinctive genetics that characterizes pRCC and ChRCC and how this information has the potential to inform patient treatment and clinical trials.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
The identification of cancer drivers is a cornerstone to the delivery of precision oncology. So far, sequencing of renal cell cancer (RCC) has largely been confined to the clear cell subtype of RCC. In contrast, sequencing analyses of the less common forms of RCC, papillary RCC (pRCC) and chromophobe RCC (ChRCC), have so far been limited. We analyzed whole-genome sequencing data on 164 tumor–normal pairs from the Genomics England 100,000 Genomes Project, providing a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genomic features, including mutational signatures, intratumor heterogeneity, and analysis of extrachromosomal DNA formation. Our research establishes correlations between genomic alterations and histologic diversification and the extent to which genetically-mediated immune escape contributes to the development of these RCC subtypes.Implications:We demonstrate the distinctive genetics that characterizes pRCC and ChRCC and how this information has the potential to inform patient treatment and clinical trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S15: Summary of mutations explained by COSMIC signatures. Signatures which are suspected to be signature artifacts are not included. Percentage of mutation burden refers to the percentage of either the total single base substitutions (SBS) or indels (ID) explained by a COSMIC signature for each patient. ChRCC, chromophobe renal cell carcinoma; ID1, slippage during DNA replication of the replicated DNA strand; ID2, slippage during DNA replication of the replicated DNA strand; ID12, unknown aetiology; pRCC, papillary renal cell carcinoma SBS1, spontaneous deamination of 5-methylcytosine (clock-like signature); SBS5, unknown (clock-like signature); SBS26, defective DNA mismatch repair; SBS44, defective DNA mismatch repair.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S15: Summary of mutations explained by COSMIC signatures. Signatures which are suspected to be signature artifacts are not included. Percentage of mutation burden refers to the percentage of either the total single base substitutions (SBS) or indels (ID) explained by a COSMIC signature for each patient. ChRCC, chromophobe renal cell carcinoma; ID1, slippage during DNA replication of the replicated DNA strand; ID2, slippage during DNA replication of the replicated DNA strand; ID12, unknown aetiology; pRCC, papillary renal cell carcinoma SBS1, spontaneous deamination of 5-methylcytosine (clock-like signature); SBS5, unknown (clock-like signature); SBS26, defective DNA mismatch repair; SBS44, defective DNA mismatch repair.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S11: Significant genomic alterations in ChRCC (n = 59). Alterations are highlighted in grey. Each column represents a sample.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S11: Significant genomic alterations in ChRCC (n = 59). Alterations are highlighted in grey. Each column represents a sample.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S11: Summary table of non-coding drivers. Only results with Q < 0.05 in either OncodriveFML or ActiveDriverWGSR are displayed. Only non-hypermutated samples are included. ChRCC,: chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Table S11: Summary table of non-coding drivers. Only results with Q < 0.05 in either OncodriveFML or ActiveDriverWGSR are displayed. Only non-hypermutated samples are included. ChRCC,: chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma; SNV, single nucleotide variant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S2: Overview of stage two of the copy-number-alteration-calling pipeline. SNV, single nucleotide variant; VAF, variant allele frequency.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing
Supplementary Figure S2: Overview of stage two of the copy-number-alteration-calling pipeline. SNV, single nucleotide variant; VAF, variant allele frequency.